Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences

Author(s): Graziella Cappelletti, Daniele Cartelli, Michael S. Christodoulou, Daniele Passarella

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 5 , 2017

Become EABM
Become Reviewer
Call for Editor


Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy in neurodegeneration, look at the results achieved and discuss the future perspectives.

Keywords: Microtubule, neurodegeneration, neuroprotection, therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 22 March, 2017
Page: [784 - 808]
Pages: 25
DOI: 10.2174/1381612822666161214150544
Price: $65

Article Metrics

PDF: 27